Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages 1389-1396

  Noh, Sung Hoon ^a   Park, Sook Ryun ^b   Yang, Han Kwang ^c   Chung, Hyun Cheol ^d   Chung, Ik Joo ^e   Kim, Sang Woon ^f   Kim, Hyung Ho ^g   Choi, Jin Hyuk ^h   Kim, Hoon Kyo ⁱ   Yu, Wansik ^j   Lee, Jong Inn ^k   Shin, Dong Bok ^l   Ji, Jiafu ^m   Chen, Jen Shi ⁿ   Lim, Yunni ^o   Ha, Stella ^o   Bang, Yung Jue ^c  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Ajou University Medical CentSuwon   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

^j Kyungpook National University School of Medicine   (South Korea)

^k Korea Institute of Radiation and Medical Science   (South Korea)

^l Gachon University   (South Korea)

^m PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁿ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^o Division of Research   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX;

ABSENCE OF SIDE EFFECTS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATION; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SOUTH KOREA; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; TREATMENT DURATION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 84908655254     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70473-5     Document Type: Article

References (24)

1. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg 1988, 187:597-603.
2. Adachi Y, Kamakura T, Mori M, Baba H, Maehara Y, Sugimachi K Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 1994, 81:414-416.
3. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A Gastric Cancer Working Group report. Jpn J Clin Oncol 2010, 40(suppl 1):I28-I37.
4. Guidelines for Diagnosis and Treatment of Carcinoma of the Stomach Japanese Gastric Cancer Society, (accessed Oct 6, 2013). http://www.jgca.jp/pdf/Guidelines2004_eng.pdf.
5. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):V50-V54.
6. Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011, 60:1449-1472.
7. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011, 22(suppl 5):V1-V9.
8. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer (including cancer in the proximal 5cm of the stomach). Version 2 National Comprehensive Cancer Network (NCCN), (accessed Feb 24, 2014). http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
9. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11:439-449.
10. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006, 7:309-315.
11. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004, 240:808-816.
12. Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003, 27:153-158.
13. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
14. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
15. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
16. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, 379:315-321.
17. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387-4393.
18. AJCC Cancer Staging Manual 2003, Springer-Verlag, New York, NY. 6th Edition. F.L. Greene, D.L. Page, I.D. Fleming (Eds.).
19. Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.
20. Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014, 25:1373-1378.
21. Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012, 104:361-366.
22. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012, 30:268-273.
23. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
24. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-1471.